XML 81 R49.htm IDEA: XBRL DOCUMENT v2.4.0.6
Joint Ventures and Other Equity Method Affiliates - Textual (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 12 Months Ended
Sep. 30, 2011
Sep. 30, 2011
Sep. 30, 2011
Johnson & Johnson Merck Consumer Pharmaceuticals Company [Member]
Sep. 30, 2011
Johnson & Johnson Merck Consumer Pharmaceuticals Company [Member]
Sep. 30, 2012
AstraZeneca LP [Member]
Dec. 31, 2008
AstraZeneca LP [Member]
Equity Income from Affiliates [Line Items]            
Limited partner interest in AZLP           1.00%
General partner interest in AZLP           99.00%
Agreed-upon payment to be made by AstraZeneca at closing for exercise of option         $ 327  
Multiple of average annual profit allocation to be included in option exercise price         10  
Years prior to option exercise to be included in average annual profit allocation portion of exercise price         3 years  
Percentage of ownership interest in equity method investment sold by Merck     50.00% 50.00%    
Proceeds from sale of interest in equity method investment     175 175    
Gain on disposition of interest in equity method investment $ 136 $ 136   $ 136